Biomea Fusion (BMEA) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Biomea Fusion Price Target Cut to $16.00/Share From $128.00 by D. Boral Capital
Dow JonesJan 13 13:44 ET · Ratings
D. Boral Capital Initiates Biomea Fusion(BMEA.US) With Buy Rating, Announces Target Price $16
Moomoo NewsJan 13 10:33 ET · Ratings
Biomea Fusion to Become Diabetes, Obesity Medicines Company
TipRanksJan 13 09:16 ET
Express News | Biomea Fusion: Based on Most Recent Trial Results, Strategic Focus for Icovamenib Will Be in Metabolic Disorders
ReutersJan 13 09:01 ET
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
GlobeNewswireJan 13 09:00 ET
Biomea Fusion Is Maintained at Buy by D. Boral Capital
Dow JonesJan 10 08:06 ET · Ratings

Comments

Kraks

8 hours ago

No bottom?

$Biomea Fusion (BMEA.US)$ is on a free fall, no bottom in view...

我要向钱看

Jan 13 08:07

UPDATES

$Biomea Fusion (BMEA.US)$ Biomea Fusion (NASDAQ: BMEA) announced its strategic transformation into a diabetes and obesity medicines company, focusing on icovamenib development for metabolic disorders. The company will conclude its oncology studies and explore partnerships for these assets.
Key clinical trial results for icovamenib showed:
1.5% mean reduction in HbA1c in severe insulin deficient patients vs placebo
1.0% HbA1c reduction in patients on GLP-1-based therapies
100% response ...

Jaguar8

Jan 13 08:05

NEWS

$Biomea Fusion (BMEA.US)$
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
Monday, 13th January at 9:00 am
Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones
of the metabolic franchise
Biomea preparing icovamenib for late-stage clinical development
2025 corporate update to be presented at the 43rd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company...

1

我要向钱看

Jan 10 07:13

🤔🤔🤔

$Biomea Fusion (BMEA.US)$ Biomea Fusion Price Target Maintained With a $128.00/Share by D. Boral Capital

2

我要向钱看

Jan 7 08:21

NEW PRECLINICAL DATA

$Biomea Fusion (BMEA.US)$ New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass compared to semaglutide alone
Icovamenib, in combination with semaglutide, approximately doubled C-peptide production per unit of glucose compared to semaglutide alone leading to a 60% improved reduction of fasting blood glucose
Ex vivo human islet experiments pr...

3

BMEA Biomea Fusion

Trade Overview

Capital Trend

News

Comments

Trending Stocks